Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Eau Claire, Wisconsin Clear all
Active, not recruiting Phase 3 Interventional

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

NCT03775265
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Atezolizumab, Biopsy of Bladder, Cisplatin, Computed Tomography, Cystoscopy, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Quality-of-Life Assessment, Radiation Therapy, Survey Administration, Transurethral Resection of Bladder Tumor
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
366
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 274 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Recruiting Not applicable Interventional

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

NCT06630104
View directory record Official record
Conditions
Lymphoproliferative Disorder, Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Electronic Health Record Review, Follow-Up, Genetic Counseling, Genetic Testing
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

NCT01349322
View directory record Official record
Conditions
Breast Cancer
Interventions
Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost, Sequential boost
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
2,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
386
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 304 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Completed Phase 3 Interventional Results available

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

NCT03578081
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
565
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Kingman, Arizona + 372 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 23, 2026, 3:37 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

NCT02749903
View directory record Official record
Conditions
Salivary Cancer
Interventions
enzalutamide
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
287
States / cities
Anchorage, Alaska • Anaheim, California • Baldwin Park, California + 201 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer

NCT00079274
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Stage III Colon Cancer
Interventions
irinotecan hydrochloride, oxaliplatin, leucovorin calcium, fluorouracil, cetuximab, Locally Directed Therapy
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
3,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
858
States / cities
Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 538 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Completed No phase listed Observational Results available

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NCT02154490
View directory record Official record
Conditions
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Docetaxel, Durvalumab, Erlotinib Hydrochloride, FGFR Inhibitor AZD4547, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Palbociclib, Pharmacological Study, Rilotumumab, Talazoparib, Taselisib, Tremelimumab
Drug · Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
998
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 639 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Jul 23, 2026, 3:37 PM EDT
Completed Not applicable Interventional

Slow Opioid Tapering Pilot Study of Patients Using Chronic Opioid Therapy

NCT05297396
View directory record Official record
Conditions
Chronic Pain, Opioid Use
Interventions
Slow Tapering of Chronic Opioid Therapy
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Eau Claire, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination

NCT06395168
View directory record Official record
Conditions
Breast Feeding
Interventions
Combined Newborn and Lactation Visit
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Eau Claire, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mayo Clinic Family Medicine Resident Wellness Study

NCT05148221
View directory record Official record
Conditions
Sleep Patterns
Interventions
Questionnaires, Actigraph and activPAL devices
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Eau Claire, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Jul 23, 2026, 3:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

NCT02438722
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
638
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Jonesboro, Arkansas + 406 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Completed No phase listed Observational Results available

S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer

NCT02728804
View directory record Official record
Conditions
Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
537
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Antioch, California + 343 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 23, 2026, 3:37 PM EDT
Recruiting Not applicable Interventional

Acute Kidney Injury In Care Transitions (ACT): Pragmatic Clinical Trial

NCT07670520
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Acute Kidney Injury in Care Transitions (ACT), Usual Care
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Completed Phase 2 Interventional Results available

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

NCT03377556
View directory record Official record
Conditions
ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, FANCC Gene Mutation, FANCD2 Gene Mutation, FANCF Gene Mutation, FANCM Gene Mutation, NBN Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, RPA1 Gene Mutation, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
Other · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1151
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 713 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jul 23, 2026, 3:37 PM EDT
Completed Phase 2 Interventional Results available

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

NCT02595905
View directory record Official record
Conditions
Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Cisplatin, Laboratory Biomarker Analysis, Placebo Administration, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
798
States / cities
Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 542 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Recruiting Not applicable Interventional

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

NCT05896189
View directory record Official record
Conditions
Breast Cancer, Cognitive Impairments
Interventions
Arm 1: Computerized Cognitive Training-Global Stimulation Games, Arm 2: Computerized Cognitive Training-Neuroplasticity Games
Behavioral
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 100 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
673
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 483 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

NCT02785952
View directory record Official record
Conditions
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1201
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Active, not recruiting Phase 2 Interventional

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

NCT05781321
View directory record Official record
Conditions
Glioblastoma
Interventions
Accelerated Hypofractionated Radiation Therapy, Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide, Biospecimen Collection
Radiation · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Active, not recruiting Phase 3 Interventional

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01863550
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Quality-of-Life Assessment
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,087 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2034
U.S. locations
909
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Hot Springs, Arkansas + 551 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 23, 2026, 3:37 PM EDT
Completed Phase 2 Interventional Results available

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT03845296
View directory record Official record
Conditions
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Rucaparib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
950
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jul 23, 2026, 3:37 PM EDT
Active, not recruiting Phase 2 Interventional Results available

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

NCT05246670
View directory record Official record
Conditions
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Palmidrol, Placebo Administration, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Middletown, Connecticut • Urbana, Illinois • Sioux City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 23, 2026, 3:37 PM EDT
Completed Phase 3 Interventional Results available

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

NCT03768414
View directory record Official record
Conditions
Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Distal Bile Duct Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Gallbladder Cancer AJCC v8, Stage IVB Gallbladder Cancer AJCC v8, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
692
States / cities
Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 448 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

NCT03793179
View directory record Official record
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Pemetrexed, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1082
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 695 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 3:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CB-17-08 Augmented Endoscopy System for Mucosal Lesion Detection During Colonoscopy for Colon Rectal Cancer.

NCT03954548
View directory record Official record
Conditions
Colorectal Cancer
Interventions
CB-17-08 CADe
Device
Lead sponsor
Cosmo Artificial Intelligence-AI Ltd
Industry
Eligibility
45 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Scottsdale, Arizona • Danville, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Jul 23, 2026, 3:37 PM EDT